Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.



Flavio Mantelli appointed Chief Medical Officer

New management for the Dompé Ophthalmology Division: Flavio Mantelli appointed Chief Medical Officer

    An Italian ophthalmologist, with professional training and academic experience acquired in Italy and in the USA, Mantelli becomes the coordinator of the company Research & Development activities within an area characterised by the great innovation potential of the molecules under study.

Milano, 6 February 2015. Dompé, an Italian biopharmaceutical company operating in the research & development of new therapeutic solutions for the treatment of rare and “orphan” diseases, has announced the appointment of Flavio Mantelli as Chief Medical Officer Ophthalmology. This position falls under the broadest spectrum of the Research & Development structure focused on areas with a high demand for healthcare such as diabetology, organ transplants and oncology. Mantelli will assume complete responsibility for all projects and activities within this development area where Dompé holds a strong leading position in the global market. Ophthalmology is one of the main areas of focus for the company which is currently concentrating in the Research & Development of innovative solutions based on rhNGF (the human recombinant variant of the Nerve Growth Factor, a molecule discovered by Professor Rita Levi Montalcini), now studied for the treatment of rare diseases (such as neurotrophic keratitis and retinitis pigmentosa) as well as for the treatment of dry eye syndrome.

Flavio Mantelli, born in Rome in 1980, is the author of 40 international scientific publications and of numerous chapters in volumes about ophthalmology. He has earned a PhD in the research of the regenerative role of NGF in ocular degenerative syndromes. He established his career at University of Rome” Campus Bio-Medico”, with several assignments to prestigious universities such as Harvard University and Policlinico Universitario San Raffaele, Milan. Regarded as among the world's foremost experts on corneal diseases, he was appointed Adjunct Assistant Professor of Biology at Temple University of Philadelphia. He joined Dompé in 2014 to coordinate research activities in North-America.

“A particularly dynamic year is on the horizon for our company, one that in the ophthalmology segment will be characterised by some crucial milestones. Flavio Mantelli has the ideal profile for this path that will see Dompé reconfirm its commitment on a global scale, with a growing presence also on the North-American continent where we are planning the launch of new clinical studies for the evaluation of the safety and efficacy of rhNGF – explains Eugenio Aringhieri, Dompé CEO. His experience, skills and expertise, combined with the potential of the molecule pipeline under development, represent the basis for the success of our research aiming at identifying innovative treatment solutions in critical healthcare areas that will benefit Patients worldwide”.

In his new role, Flavio Mantelli will also be responsible for managing the current and soon to be launched clinical trials on ophthalmology. “The research in this area is extremely advanced since Dompé has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L'Aquila. – explains Mantelli. It is indisputable that we have come a long way from the first experimental studies to the clinical trial currently under way. It is therefore with great enthusiasm that I take the opportunity to contribute to this project with the firm conviction that with the cooperation of the entire research team we will be able to achieve important results for the cure of diseases that, to date, remain untreated”.